ArticleInternational journal of oncology2018
Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination.
Article in International journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Beckwith-Wiedemann syndrome and large offspring syndrome involve alterations in methylome, transcriptome, and chromatin configuration.NAR molecular medicine · 2025Article
- The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.Discover oncology · 2025Article
- Gene Expression Analysis and Validation of a Novel Biomarker Signature for Early-Stage Lung Adenocarcinoma.Biomolecules · 2025Article
- Identification of PECAM1 as a Prognostic Biomarker for Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Role of adhesion molecules in cancer and targeted therapy.Science China. Life sciences · 2024Review
- A gene chip study suggests that miR-17-3p is associated with diabetic foot ulcers.International wound journal · 2023Article
- Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.Genetics research · 2023Article
- Review
- Adhesion Molecules ICAM-1 and PECAM-1 as Potential Biomarkers of Central Nervous System Damage in Women Breast Cancer Survivors.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- The angiogenic genes predict prognosis and immune characteristics in esophageal squamous cell carcinoma: Evidence from multi-omics and experimental verification.Frontiers in oncology · 2022Article
- Endothelial Glycocalyx-Mediated Intercellular Interactions: Mechanisms and Implications for Atherosclerosis and Cancer Metastasis.Cardiovascular engineering and technology · 2021Review
- Proteomics and its applications in breast cancer.American journal of cancer research · 2021Review
- Analysis of expression levels of markers associated with tumor proliferation and angiogenesis in familial adenomatous polyposis.Molecular genetics & genomic medicine · 2020Article
- Constructing cancer patient-specific and group-specific gene networks with multi-omics data.BMC medical genomics · 2020Article
- Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- FBN1 promotes DLBCL cell migration by activating the Wnt/β-catenin signaling pathway and regulating TIMP1.American journal of translational research · 2020Article
- Interactive Verification Analysis of Multiple Sequencing Data for Identifying Potential Biomarker of Lung Adenocarcinoma.BioMed research international · 2020Article
- Metformin reverses the drug resistance of cisplatin in irradiated CNE-1 human nasopharyngeal carcinoma cells through PECAM-1 mediated MRPs down-regulation.International journal of medical sciences · 2020Article
- Development of A New Mouse Model for Intrahepatic Cholangiocellular Carcinoma: Accelerating Functions of Pecam-1.Cancers · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet endothelial cell adhesion molecule‑1 (PECAM‑1) is expressed on the vascular endothelium and has been implicated in the late progression of metastatic tumors. The activity of PECAM‑1 appears to be mediated by modulation of the tumor microenvironment (TME) and promotion of tumor cell proliferation, rather than through the stimulation of tumor angiogenesis. The present study aimed to extend those initial findings by indicating that the presence of functional PECAM‑1 on the endothelium promotes a proliferative tumor cell phenotype in vivo, as well as in tumor cell (B16‑F10 melanoma and 4T1 breast cancer cell lines) co‑culture assays with mouse endothelial cells (ECs) or a surrogate EC line (REN‑MP). The pro‑proliferative effects were mediated by soluble endothelial‑derived factors that were dependent on PECAM‑1 homophilic ligand interactions, but which were independent of PECAM‑1‑dependent signaling. Further analysis of the conditioned media obtained from tumor/EC and tumor/REN‑MP co‑cultures identified TIMP metallopeptidase inhibitor‑1 (TIMP‑1) as a PECAM‑1‑regulated factor, the targeting of which in the tumor cell/REN‑MP system inhibited tumor cell proliferation. In addition, TIMP‑1 expression was decreased in metastatic tumors from the lungs of PECAM‑1‑null mice, thus providing evidence of the in vivo significance of co‑culture studies. Taken together, these studies indicated that endothelial PECAM‑1, through PECAM‑1‑dependent homophilic binding interactions, may induce release of TIMP‑1 from the endothelium into the TME, thus leading to increased tumor cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.